Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2020-04-21 AGM Information
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING
AGM Information Classification · 95% confidence The document is a 'Form of Proxy' for the Annual General Meeting (AGM) of Alphamab Oncology scheduled for May 25, 2020. It includes instructions for shareholders to appoint proxies to vote on resolutions at the AGM, such as receiving audited financial statements, granting mandates to directors, re-electing directors, and appointing auditors. This type of document is used to facilitate voting at the AGM and is not the AGM presentation materials themselves, nor is it the actual Annual Report or financial statements. It is a proxy form related to the AGM, which falls under the category of AGM Information (AGM-R). The document length and content confirm it is not a brief announcement or a report publication notice, but a detailed proxy form for the AGM.
2020-04-21 English
(1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES&#x3b; (2) PROPOSED ADOPTION OF POST-IPO SHARE OPTION SCHEME&#x3b; (3) PROPOSED RE-ELECTION OF THE RETIRING DIRECT
AGM Information Classification · 100% confidence The document is a circular from Alphamab Oncology dated April 22, 2020, containing detailed information about the upcoming Annual General Meeting (AGM) scheduled for May 25, 2020. It includes proposals for granting general mandates to repurchase and issue shares, adoption of a post-IPO share option scheme, re-election of retiring directors, re-appointment of auditors, and the notice of the AGM itself. The document is comprehensive, exceeding 15,000 characters, and includes detailed appendices and definitions related to the AGM agenda items. It is not a simple announcement or notice but a full circular providing materials and information for the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2020-04-21 English
2019 Annual Report
Annual Report Classification · 100% confidence The document is titled '2019 Annual Report' for Alphamab Oncology and contains detailed sections typical of an annual report, including company profile, corporate information, chairman's statement, management discussion and analysis, corporate governance report, directors' report, independent auditor's report, consolidated financial statements, and notes to the financial statements. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and operational information for the fiscal year 2019, consistent with an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K). FY 2019
2020-04-21 English
VOLUNTARY ANNOUNCEMENT - JIANGSU ALPHAMAB RECEIVED THE SAFE TO PROCEED LETTER FROM THE U.S. FDA FOR A PHASE II CLINICAL TRIAL OF KN046 FOR NSCLC IN THE UNITED STATES
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding receiving a 'Safe to Proceed Letter' from the U.S. FDA for a Phase II clinical trial of a drug candidate. It is an update on a regulatory approval related to clinical trial progress, not a financial report, earnings release, or management discussion. The document is relatively short (4535 characters) and serves as a business update rather than a detailed report or presentation. It does not contain financial data, voting results, or governance information. It is not a regulatory filing in the strict sense of compliance documents but rather a voluntary business announcement. Given the content and nature, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other categories.
2020-04-15 English
ADOPTION OF THE POST-IPO SHARE OPTION SCHEME
Capital/Financing Update Classification · 95% confidence The document is an announcement from Alphamab Oncology regarding the adoption of a Post-IPO Share Option Scheme. It discusses the plan to adopt the scheme, the need for approval from the listing committee and shareholders, and mentions a forthcoming circular and general meeting for approval. The document is relatively short (2659 characters) and does not contain financial statements or detailed financial data. It is an announcement about a capital-related plan (share option scheme) and the process for approval, not the actual scheme document or detailed financial report. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes such as share option schemes.
2020-04-14 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2020
Share Issue/Capital Change Classification · 95% confidence The document is a detailed monthly report on movements in securities for the issuer Alphamab Oncology, dated for the month ended 31/03/2020. It includes detailed tables on movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The document is addressed to the Hong Kong Exchanges and Clearing Limited, indicating it is a regulatory filing related to share capital changes. The content focuses on share capital movements and confirmations related to securities issuance, with no financial performance data, earnings, management discussion, or audit information. It is not an announcement of a report but a substantive regulatory disclosure. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues, stock splits, or other capital changes.
2020-04-03 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.